{
    "doi": "https://doi.org/10.1182/blood.V110.11.4478.4478",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1050",
    "start_url_page_num": 1050,
    "is_scraped": "1",
    "article_title": "Radioimmunotherapy (RIT) with 90 Y-Ibritumomab Tiuxetan (Zevalin) for the Treatment of Relapsed or Resistant Aggressive Diffuse Large B-Cell Lymphoma (DLBCL) Heavily Pretreated with Rituximab + Chemotherapy: A GIMURELL Experience. ",
    "article_date": "November 16, 2007",
    "session_type": "Publication Only",
    "topics": [
        "chemotherapy regimen",
        "diffuse large b-cell lymphoma",
        "ibritumomab tiuxetan",
        "radioimmunotherapy",
        "rituximab",
        "autologous stem cell transplant",
        "non-hodgkin's lymphoma, aggressive",
        "bone marrow involvement",
        "receptors, complement 3d",
        "antibodies"
    ],
    "author_names": [
        "Barbara Botto",
        "Marilena Bello\u0300",
        "Giulia Benevolo",
        "Maria Giuseppina Cabras",
        "Claudia Castellino",
        "Annalisa Chiappella",
        "Giuseppe Fioritoni",
        "Roberto Freilone",
        "Maurizio Martelli",
        "Lorella Orsucci",
        "Patrizia Pregno",
        "Paola Scapoli",
        "Anna Tonso",
        "Giovanni Bisi",
        "Umberto Vitolo",
        "Eugenio Gallo"
    ],
    "author_affiliations": [
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Nuclear Medicin, ASO S. Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Hematology, Ospedale Oncologico A. Businco, Cagliari"
        ],
        [
            "Hematology, Ospedale S. Croce e Carle, Cuneo"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Hematology, Ospedale Civile, Pescara"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Hematology, Policlinico Umberto I University La Sapienza, Roma"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Nuclear Medicin, ASO S. Giovanni Battista, Torino"
        ],
        [
            "Medicin, Ospedale degli Infermi, Biella, Italy"
        ],
        [
            "Nuclear Medicin, ASO S. Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ],
        [
            "On Behalf of Gruppo Italiano Multiregionale per lo Studio dei Linfomi e delle Leucemie (GIMURELL), Hematology, ASO S. Giovanni Battista, Torino"
        ]
    ],
    "first_author_latitude": "45.073488749999996",
    "first_author_longitude": "7.67560655",
    "abstract_text": "Introduction: The addition of antibody monoclonal anti CD20 Rituximab to CHOP chemotherapy has resulted in improved CR, progression free survival and overall survival rates for patients affected by diffuse large B cell lymphoma. Recently, RIT with Zevalin has been shown effective in the treatment of relapsed refractory elderly DLBCL. We report the results of a study to evaluate the efficacy and safety of Zevalin in relapsed or chemoresistant aggressive lymphoma previously treated with Rituximab. Patients and methods: Elegibility criteria were as follows: age over 18 years, refractory or chemoresistant CD20+ aggressive lymphoma (grade III follicular, PML or DLBCL de novo) WHO performance status of 0 to 2, stage II bulky, III or IV, bone marrow involvement < 25%, written informed consent in accordance with institutional guidelines. All patients were previously treated with Rituximab and almost two lines of chemotherapy. Patients with pre-treatment platelet counts of > 150.000/mm 3 received Zevalin at 0.4 mCi/kg whereas those with platelets < 150.000/mm 3 received 0.3 mCi/kg. Results: Fourteen patients were treated with RIT: 5 patients were stage II, 3 stage III, 6 stage IV (5 with bone marrow involvement). Six patients had grade III follicular, 4 primary mediastinal and 4 DLBCL de novo. Ten patients received 0.4 mCi/kg and 4 patients 0.3 mCi/kg. Five chemoresistant patients after 2 or more lines chemoimmunotherapy received RIT in combination with BEAM and subsequent autologous stem cell transplantation (ASCT) and 9 patients were treated with Zevalin alone. Two months after RIT we reported CR 4 patients, PR 5 patients and no response/progression 5 patients (ORR 9/14 patients 64%). All 5 patients treated with RIT + BEAM + ASCT achieved a response (CR 2 patients and PR 3 patients ORR 100%). ORR in 9 patients treated with RIT alone was 46% (CR 2 patients and PR 2 patients). No toxic deaths were observed, two patients died of lymphoma (one patients 1 year after Zevalin infusion and the second progressed and died 5 months after RIT). The most common grade 3\u20134 AE were neutropenia and thrombocytopenia. Discussion: RIT with 90 Y-Ibritumomab Tiuxetan is a safe and effective approach for patients affected by aggressive lymphoma and heavily pretreated with Rituximab + chemotherapy. The effective role of RIT alone or in combination with high dose chemotherapy + ASCT as salvage therapy has to be studied in this subset of patients."
}